Naloxone Affordability Act of 2023

Summary

Naloxone Affordability Act of 2023 This bill requires the Government Accountability Office to study access to and affordability of naloxone (a medication that temporarily reverses opioid overdoses). The study must address matters related to out-of-pocket costs that consumers pay for naloxone and coverage for naloxone as an over-the-counter drug through Medicare, Medicaid, and private health insurance. Historically, naloxone required a prescription and so was typically covered by health insurance. However, the Food and Drug Administration approved Narcan (a naloxone hydrochloride nasal spray) for use without a prescription on March 29, 2023, and health insurance does not generally cover over-the-counter medications.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 12 June 2023

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 12 June 2023

   Introduced

   Introduced in House

   Source: IntroReferral

3. 12 June 2023

   Introduced

   Introduced in House

   Source: IntroReferral

4. 16 June 2023

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 12 June 2023 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 12 June 2023

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 12 June 2023

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 12 June 2023

  Open at official source

Sponsors

• Ann Kuster · D · Sponsor
• Sen. Blunt Rochester, Lisa [D-DE] · D · Sponsor
• Angie Craig · D · Sponsor
• · hsif00 · Standing

Related records

• related to → STOP Fentanyl Overdoses Act of 2023
• related to → Pharmacy Benefit Manager Reform Act
• related to → Stop Fentanyl Overdoses Act of 2023